NCT00821483View on ClinicalTrials.gov

A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine

PHASE3CompletedINTERVENTIONAL
Enrollment

298

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Migraine
Interventions
DRUG

Frovatriptan

2.5mg, qd

All Listed Sponsors
lead

SK Chemicals Co., Ltd.

INDUSTRY

NCT00821483 - A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine | Biotech Hunter | Biotech Hunter